Risk of acute liver injury following the nirmatrelvir/ritonavir use.
Carlos King-Ho WongLoey Lung-Yi MakIvan Chi Ho AuWing Yiu ChengChing Hei SoKristy Tsz Kwan LauEric Ho Yin LauBenjamin John CowlingGabriel Matthew LeungMan Fung YuenPublished in: Liver international : official journal of the International Association for the Study of the Liver (2023)
The risk of ALI associated with nirmatrelvir/ritonavir treatment for COVID-19 was elevated in the pre-exposure period, but not following nirmatrelvir/ritonavir initiation. ALI following nirmatrelvir/ritonavir treatment were mostly mild and less severe than ALI events in non-nirmatrelvir/ritonavir users.